ArticleCancer management and research2025
COVID-19 and Breast Cancer Prognosis: A Comparative Analysis of Disease-Free Survival Rates in Taiwan.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of the COVID-19 pandemic and its measures on one-year and three-year cancer survival using Swiss cantonal cancer registry data.Cancer causes & control : CCC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study evaluates the effect of pandemic-related diagnostic and treatment delays on 3-year disease-free survival (DFS) in Taiwanese breast cancer patients. Material and Methods: This single-institution study analyzed breast cancer patients across three distinct periods: non-COVID-19 in 2017, pre-COVID-19 in 2019, and during the COVID-19 pandemic in 2020, to investigate the impact of the COVID-19 pandemic on DFS rates and recurrence rates. DFS was defined as the interval from surgery to the occurrence of breast cancer recurrence or death, whereas overall survival (OS) was defined as the interval from surgery to death from any cause. Follow-up protocol included regular clinical examinations and annual imaging, with a minimum follow-up of 36 months unless an event occurred earlier. Results: The demographics of breast cancer patients changed from 2017 to 2020, with an average age increasing from 54.6 to 58.6 years. While overall survival (OS) did not vary significantly across the cohorts, DFS differed significantly, with the 2020 cohort experiencing a significant decline in DFS compared to 2017 (p = 0.027). Recurrence rates also increased, from 3.1% in 2017 to 7.6% in 2020. Conclusion: The COVID-19 pandemic had a negative impact on the DFS of breast cancer patients, with the 2020 cohort experiencing a significantly shorter DFS time compared to the 2017 cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.